UPDATED LIFETIME SURVIVAL ESTIMATES FOR NIVOLUMAB plus IPILIMUMAB IN PREVIOUSLY UNTREATED ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA (1L ARCC)

被引：0
|
作者：
Qendri, V [1 ]
May, J. [2 ]
Malcolm, B. [2 ]
Ejzykowicz, F. [3 ]
Kurt, M. [3 ]
Cakar, E. [1 ]
Klijn, S. [1 ]
机构：
[1] Pharmerit, Rotterdam, Netherlands
[2] Bristol Myers Squibb, Uxbridge, Middx, England
[3] Bristol Myers Squibb, Princeton, NJ USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDG5
引用
收藏
页码：S520 / S520
页数：1
相关论文
共 50 条
  • [1] STABILITY OF LIFETIME OVERALL SURVIVAL ESTIMATES OF NIVOLUMAB plus IPILIMUMAB IN FIRST-LINE ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA
    Cakar, E.
    May, J.
    Malcolm, B.
    Gooden, K. M.
    Klijn, S.
    VALUE IN HEALTH, 2019, 22 : S517 - S518
  • [2] LIFETIME SURVIVAL ESTIMATES FOR NIVOLUMAB plus IPILIMUMAB AND SUNITINIB IN PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED/METASTATIC INTERMEDIATE- OR POOR (I/P)-RISK RENAL CELL CARCINOMA (1L ARCC) BASED ON 5-YEAR MINIMUM FOLLOW-UP DATA FROM CHECKMATE 214
    Qendri, V
    May, J. R.
    Ejzykowicz, F.
    Kurt, M.
    Cakar, E.
    Klijn, S.
    VALUE IN HEALTH, 2022, 25 (01) : S24 - S24
  • [3] COMPARISON OF ADVERSE EVENT COSTS OF NIVOLUMAB plus IPILIMUMAB VERSUS SUNITINIB FOR PREVIOUSLY UNTREATED INTERMEDIATE-/POOR-RISK ADVANCED RENAL CELL CARCINOMA IN SPAIN
    Polanco Sanchez, C.
    Gooden, K. M.
    May, J.
    Malcolm, B.
    Du, E. X.
    Yin, L.
    Betts, K.
    VALUE IN HEALTH, 2019, 22 : S458 - S458
  • [4] COMPARISON OF ADVERSE EVENT COSTS OF NIVOLUMAB plus IPILIMUMAB VERSUS SUNITINIB FOR PREVIOUSLY UNTREATED INTERMEDIATE-/POOR-RISK ADVANCED RENAL CELL CARCINOMA IN SWITZERLAND
    Oniangue-Ndza, C.
    Gooden, K. M.
    May, J.
    Malcolm, B.
    Du, E. X.
    Yin, L.
    Betts, K. A.
    VALUE IN HEALTH, 2019, 22 : S457 - S457
  • [5] COMPARISON OF ADVERSE EVENT COSTS OF NIVOLUMAB plus IPILIMUMAB VERSUS SUNITINIB FOR PREVIOUSLY UNTREATED INTERMEDIATE-/POOR-RISK ADVANCED RENAL CELL CARCINOMA IN PORTUGAL
    Alves, D.
    Polanco Sanchez, C.
    Gooden, K. M.
    May, J.
    Malcolm, B.
    Du, E. X.
    Yin, L.
    Betts, K. A.
    VALUE IN HEALTH, 2019, 22 : S463 - S463
  • [6] Checkmate 214 Post Hoc Analyses of Nivolumab Plus Ipilimumab or Sunitinib in IMDC Intermediate/Poor-Risk Patients with Previously Untreated Advanced Renal Cell Carcinoma (ARCC) with Sarcomatoid Features (SRCC)
    Grimm, Marc-Oliver
    Mcdermott, David F.
    Choueiri, Toni K.
    Motzer, Robert J.
    Frontera, Osvaldo Aren
    George, Saby
    Powles, Thomas
    Donskov, Frede
    Harrison, Michael R.
    Rodriguez-Cid, Jeronimo
    Ishii, Yuko
    Mchenry, Brent
    Rini, Brian I.
    Tannir, Nizar M.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 70 - 71
  • [7] CheckMate 214 Retrospective Analyses of Nivolumab Plus Ipilimumab or Sunitinib in IMDC Intermediate/Poor-Risk Patients With Previously Untreated Advanced Renal Cell Carcinoma With Sarcomatoid Features
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (12) : 6 - 8
  • [8] COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB plus IPILIMUMAB VERSUS SUNITINIB IN THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN SPAIN
    Polanco Sanchez, C.
    Perez-Alcantara, F.
    May, J.
    Gooden, K. M.
    Malcolm, B.
    Arranz, J. A.
    Duran, I
    Garcia-Donas, J.
    Gallardo, E.
    Lainez, N.
    Maroto, P.
    Valderrama, B. P.
    Puente, J.
    Vazquez, S.
    Van de Wetering, G.
    van Carroll, Smith L. E.
    VALUE IN HEALTH, 2019, 22 : S466 - S466
  • [9] Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland
    Cakar, Esra
    Oniangue-Ndza, Cesar
    Schneider, Ralph P. P.
    Klijn, Sven L. L.
    Vogl, Ursula M. M.
    Rothermundt, Christian
    May, Jessica R. R.
    PHARMACOECONOMICS-OPEN, 2023, 7 (04) : 567 - 577
  • [10] Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland
    Esra Çakar
    César Oniangue-Ndza
    Ralph P. Schneider
    Sven L. Klijn
    Ursula M. Vogl
    Christian Rothermundt
    Jessica R. May
    PharmacoEconomics - Open, 2023, 7 : 567 - 577
12345